Skip to content
Toggle main navigation
adMare Community logo
adMare Community logo
      Log in
      Join now
      Select an available language
      EN

      News

      Stay up-to-date on the latest industry news, with access to the most recent and relevant stories from biotechnology, pharmaceutical and life science organizations across Canada.

      Filter by category
      All
      adMare ecosystem
      Industry news
      Life science organizations

      Results (674)

      Don’t let your samples slip: Why every clinical trial needs biospecimen management

      Don’t let your samples slip: Why every clinical trial needs biospecimen management

      Managing biospecimens is a critical, yet often overlooked, part of ensuring a clinical trial’s success. Biospecimen managers are a resource that provides full lifecycle biospecimen oversight, from collection to sample disposition or long-term storage of those specimens for future exploratory needs. But how exactly does a biospecimen manager help assure the integrity and efficiency of clinical tria
      October 28, 2024
      How pharmaceutical companies can leverage print to remain agile and competitive

      How pharmaceutical companies can leverage print to remain agile and competitive

      The competitive pharmaceutical landscape has led to a surge in the global healthcare advertising market with spending expected to top $52 billion by 2028.Pharmaceutical organizations’ printing needs range from posters, brochures and direct mail to signage and banners, and print remains a preferred channel for healthcare communications. More than 76% of pharmaceutical companies used printed patient
      October 28, 2024
      J&J’s Asish Xavier on biotech’s rebound in a volatile era

      J&J’s Asish Xavier on biotech’s rebound in a volatile era

      In the world of drug discovery, a lot can change in 20 years.Over the past two decades, biotechnology companies brought to market a wave of biologic medicines that changed how many autoimmune diseases are treated. Cancer immunotherapy extended lives to a degree that previously wasn’t possible, and gene editing technology went from science fiction to marketed medicine.The amount of money flowing in
      October 24, 2024
      PureTech thinks the ‘hub-and-spoke’ startup model is still a good bet. If only investors agreed.

      PureTech thinks the ‘hub-and-spoke’ startup model is still a good bet. If only investors agreed.

      Biotechnology investors dream of success stories like Karuna Therapeutics. Founded in 2009, the company took a drug others had given up on, ironed out its flaws and then, against tremendously poor odds, ushered in a new generation of antipsychotic medications.Bristol Myers Squibb recently acquired Karuna for $14 billion. PureTech Health, the Boston-based incubator that got the company off the grou
      October 22, 2024
      Sanofi, expanding in radiopharma, strikes a joint venture deal

      Sanofi, expanding in radiopharma, strikes a joint venture deal

      Dive Brief:Sanofi will invest 300 million euros, or about $325 million, for a roughly 16% stake in a new joint venture set up to develop radiopharmaceutical drugs for rare cancers.The newly created entity will operate under the banner of Orano Med, a radiopharmaceutical developer and Sanofi’s partner in the joint venture. Orano Med, which is a subsidiary of the Orano Group, specializes in versions
      October 18, 2024
      Lundbeck to buy brain drug developer Longboard for $2.6B

      Lundbeck to buy brain drug developer Longboard for $2.6B

      Danish drugmaker Lundbeck has agreed to spend $2.6 billion acquiring a young biotechnology company with an experimental brain medicine that could become a blockbuster product.The acquisition, announced Monday, has Lundbeck paying $60 in cash for each outstanding share of Longboard Pharmaceuticals, a 54% premium to the biotech’s stock price Friday. The companies expect their deal to close before th
      October 15, 2024
      From maximizing recruitment to promoting diversity: How to deploy NGS technologies to achieve clinical trial success

      From maximizing recruitment to promoting diversity: How to deploy NGS technologies to achieve clinical trial success

      Precision oncology continues to be one of the most promising — and fastest-growing fields — in cancer therapy. Of the more than 10,000 oncology clinical trials initiated between 2019 and 2023, roughly 30% focused on precision oncology.1 And, overall, the global market for precision oncology therapeutics is expected to grow steadily over the next decade, reaching a projected $364 Billion by 2035.2H
      October 15, 2024
      Successful COA selection paves the path to drug development

      Successful COA selection paves the path to drug development

      Last year, the U.S. Food and Drug Administration approved 55 new drugs. Choosing the right clinical outcome assessments (COAs) is an important part of successfully advancing drug development and securing regulatory approval.COAs are critical to all phases of drug development, from collecting patient data to submission for regulatory approval. Their use throughout these phases ensures that the outc
      October 15, 2024
      The number of AI medical devices has spiked in the past decade

      The number of AI medical devices has spiked in the past decade

      The number of medical devices with artificial intelligence technology has risen sharply in the past decade. The Food and Drug Administration has authorized 950 AI or machine learning-enabled devices as of Aug. 7, 2024, according to the agency’s database. While the FDA authorized the first AI-enabled device in 1995, the number of submissions has spiked in recent years.In 2015, the FDA authorized si
      October 11, 2024
      Sanofi may have found a buyer for its consumer health business

      Sanofi may have found a buyer for its consumer health business

      For the past year, French pharmaceutical giant Sanofi has been searching for a buyer to take control of its consumer health business. That search may now be over.On Friday, Sanofi said it’s in negotiations with the private equity firm Clayton Dubilier & Rice for the potential sale of a 50% controlling stake in the consumer business, named Opella. Financial terms of the deal weren’t disclosed. Howe
      October 11, 2024
      AI startup Basecamp allies with the Broad to dream up ‘programmable’ genetic medicines

      AI startup Basecamp allies with the Broad to dream up ‘programmable’ genetic medicines

      Basecamp Research, a biotechnology startup focused on artificial intelligence, has raised $60 million in funding and signed a multi-year collaboration with the Broad Institute of MIT and Harvard.The London-based company said Wednesday that it will work with the lab of David Liu, a prominent gene editing researcher and biotech entrepreneur, to advance new types of “programmable” genetic medicines.
      October 9, 2024
      Virica Biotech and Ginkgo Bioworks Announce Partnership to Accelerate AAV Gene Therapy Manufacturing

      Virica Biotech and Ginkgo Bioworks Announce Partnership to Accelerate AAV Gene Therapy Manufacturing

      BOSTON & OTTAWA, Ontario--(BUSINESS WIRE)--Ginkgo Bioworks, Inc. (“Ginkgo”) which is building the leading platform for cell programming and biosecurity, and Virica Biotech Inc. (“Virica”), a leading developer of enhancers for scaling of viral vectors as well as cell and gene therapies, today announced a strategic partnership to enhance each company’s adeno-associated virus (AAV) gene therapy manuf
      October 4, 2024
      Accelerating precision oncology: The value of an end-to-end partner for therapeutic access

      Accelerating precision oncology: The value of an end-to-end partner for therapeutic access

      Precision oncology continues to be one of the fastest-growing markets within pharmaceuticals. Valued at $130 Billion in 2023, the global market is expected to grow at a CAGR of nearly 9% between 2023 and 2035 to a projected $364 Billion, reports Roots Analysis.While the field presents a tremendous opportunity, it also comes with unique challenges — such as an often small and geographically diverse
      October 1, 2024
      Roche turns to a startup in search for new breast cancer drugs

      Roche turns to a startup in search for new breast cancer drugs

      Dive Brief:Roche on Monday agreed to pay $850 million to acquire two experimental breast cancer drugs being developed by China-based biotechnology startup Regor Therapeutics.The deal hands Roche two medicines that Regor, in a statement, described as “next-generation” versions of the CDK inhibitors widely used to treat certain breast cancers. One prospect is in early-stage testing already, while th
      October 1, 2024
      AbbVie's dopamine-focused Parkinson's treatment reduces disease burden in phase 3 trial

      AbbVie's dopamine-focused Parkinson's treatment reduces disease burden in phase 3 trial

      On the same day that some Parkinson’s disease drugs are being called into question, AbbVie has announced that its late-stage monotherapy candidate has significantly reduced the burden of the disease in patients compared to placeboThe phase 3 TEMPO-1 trial tested two daily doses (5 mg and 15 mg) of tavapadon, an oral dopamine receptor agonist. Both arms beat placebo at improving disease burden at W
      September 26, 2024
      Merck bags options on Evaxion's AI-designed vaccines, offering small upfront and big back end

      Merck bags options on Evaxion's AI-designed vaccines, offering small upfront and big back end

      Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects against gonorrhea and an undisclosed infectious agent.The deal covers two candidates derived from an Evaxion technology that uses AI to identify antigens that can trigger robust, protective immune responses.
      September 26, 2024
      Flagship hopes biotechs will flock to Mirai’s algorithm-based platform to enhance their genetic meds

      Flagship hopes biotechs will flock to Mirai’s algorithm-based platform to enhance their genetic meds

      Amid the genetic medicines arms race, Flagship Pioneering is unveiling a new company to help biotechs fine-tune the precision of their therapies.The venture creation firm has loaded up Mirai Bio with an initial commitment of $50 million, funds Mirai will use to advance a platform designed to “enhance and accelerate genetic medicine development across a wide range of therapeutic areas and modalitie
      September 26, 2024
      Biogen, UCB get the lupus data they’ve waited two decades for

      Biogen, UCB get the lupus data they’ve waited two decades for

      After more than two decades of work, partners Biogen and UCB say they finally have positive results from a late-stage clinical trial evaluating one of their experimental drugs for lupus.The companies didn’t release any data, but said the drug, when paired with the current standard of care, was significantly better than a placebo at helping people with the most common form of lupus. The trial enrol
      September 24, 2024
      The Future of Communication for Industry: Embracing AI and Human Connection

      The Future of Communication for Industry: Embracing AI and Human Connection

      Courtney Walker, Chief Growth Officer at MMC and RXMosaic, discusses the evolving role of communicators and the future of the healthcare industry. AI will significantly transform the field, necessitating a shift from traditional roles to those involving deeper analysis and strategic management. She emphasized the importance of human connection and relationship-building, as AI cannot replicate thes
      September 24, 2024
      adMare BioInnovations Appoints Marc Rivière to its Board of Directors

      adMare BioInnovations Appoints Marc Rivière to its Board of Directors

      Vancouver (BC), Toronto (ON), and Montreal (QC) – September 20, 2024 – adMare BioInnovations (adMare) is pleased to announce the appointment of Dr. Marc Rivière to its Board of Directors. With extensive expertise in funding and supporting companies, combined with a strong background in drug development, his experience will be valuable in supporting adMare’s mission of building companies, building
      September 20, 2024
      Contact
      adMare BioInnovations

      Canada

      thansen@admarebio.com
      Cookies
      Reselect cookie settings
      Community engagement platform by Hivebrite.